Hadjistilianou Theodora, Coriolani Gianni, Bracco Sandra, Gennari Paola, Caini Mauro, Cerase Alfonso, Galimberti Daniela, De Francesco Sonia, De Luca Mariacarla, Mastrangelo Domenico
J Pediatr Ophthalmol Strabismus. 2014 Jan-Feb;51(1):32-8. doi: 10.3928/01913913-20131203-01. Epub 2013 Dec 10.
To report our experience with superselective ophthalmic artery infusion of melphalan (SOAIM) for macular retinoblastoma to obtain tumor control while preserving as much useful vision as possible.
Five patients with newly diagnosed unilateral retinoblastoma involving the macula were selected within a group of patients eligible for SOAIM as the primary treatment.
The mean tumor basal dimension and thickness in this group of five patients with macular retinoblastoma were 11.6 and 12.3 mm, respectively. The stage at diagnosis ranged from II to VB (Reese-Ellsworth) or B to D (International Classification System). Tumor regression with SOAIM was achieved in all cases with regression patterns type I in four cases and III in one case.
SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy.
报告我们采用超选择性眼动脉输注美法仑（SOAIM）治疗黄斑部视网膜母细胞瘤的经验，以在尽可能保留有用视力的同时实现肿瘤控制。
在符合SOAIM作为主要治疗方法的一组患者中，选择了5例新诊断的单侧黄斑部视网膜母细胞瘤患者。
这5例黄斑部视网膜母细胞瘤患者的肿瘤平均基底尺寸和厚度分别为11.6和12.3毫米。诊断时的分期范围为II至VB（里斯-埃尔斯沃思分期）或B至D（国际分类系统）。所有病例均通过SOAIM实现了肿瘤消退，其中4例为I型消退模式，1例为III型。
SOAIM在黄斑部视网膜母细胞瘤的治疗中可能具有价值。由于化疗相关的局部和全身毒性，它可能以较低的并发症发生率挽救残余视力。
Zotero 插件